Pasar al contenido principal

FUNCION DE LA HAPLOINSUFICIENCIA DE GENES REPARADORES DEL DNA EN LA PREDISPOSICION A NEUROBLASTOMA Y EN LA REGULACION DEL NICHO INMUNOSUPRESOR

PID2020-119323RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PARA LA INVESTIGACION HOSPITAL UNIVERSITARIO LA FE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Evaluation of circulating tumor DNA by electropherogram analysis and methylome profiling in high-risk neuroblastomas

  • Trinidad, Eva María
  • Juan-Ribelles, Antonio
  • Pisano, Giulia
  • Castel, Victoria
  • Cañete, Adela
  • Gut, Marta
  • Heath, Simon
  • Font de Mora, Jaime
Background: Liquid biopsy has emerged as a promising, non-invasive diagnostic approach in oncology because the analysis of circulating tumor DNA (ctDNA) reflects the precise status of the disease at diagnosis, progression, and response to treatment. DNA methylation profiling is also a potential solution for sensitive and specific detection of many cancers. The combination of both approaches, DNA methylation analysis from ctDNA, provides an extremely useful and minimally invasive tool with high relevance in patients with childhood cancer. Neuroblastoma is an extracranial solid tumor most common in children and responsible for up to 15% of cancer-related deaths. This high death rate has prompted the scientific community to search for new therapeutic targets. DNA methylation also offers a new source for identifying these molecules. However, the limited blood sample size which can be obtained from children with cancer and the fact that ctDNA content may occasionally be diluted by non-tumor cell-free DNA (cfDNA) complicate optimal quantities of material for high-throughput sequencing studies. Methods: In this article, we present an improved method for ctDNA methylome studies of blood-derived plasma from high-risk neuroblastoma patients. We assessed the electropherogram profiles of ctDNA-containing samples suitable for methylome studies, using 10 ng of plasma-derived ctDNA from 126 samples of 86 high-risk neuroblastoma patients, and evaluated several bioinformatic approaches to analyze DNA methylation sequencing data. Results: We demonstrated that enzymatic methyl-sequencing (EM-seq) outperformed bisulfite conversion-based method, based on the lower proportion of PCR duplicates and the higher percentage of unique mapping reads, mean coverage, and genome coverage. The analysis of the electropherogram profiles revealed the presence of nucleosomal multimers, and occasionally high molecular weight DNA. We established that 10% content of the mono-nucleosomal peak is sufficient ctDNA for successful detection of copy number variations and methylation profiles. Quantification of mono-nucleosomal peak also showed that samples at diagnosis contained a higher amount of ctDNA than relapse samples. Conclusions: Our results refine the use of electropherogram profiles to optimize sample selection for subsequent high-throughput analysis and support the use of liquid biopsy followed by enzymatic conversion of unmethylated cysteines to assess the methylomes of neuroblastoma patients., Supported by TRANSCAN-2 consortium LIQUIDHOPE by Fundación Científica de la Asociación Española Contra el Cáncer (TRNSC18001FON), by Spanish Ministry of Science and Innovation (PID2020-119323RB-I00 grant) and by “Sumemos muchas manos por los niños enfermos” non-profit organization.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Liquidhope: methylome and genomic profiling from very limited quantities of plasma-derived DNA

  • Trinidad, Eva María
  • Vidal, Enrique
  • Coronado, Esther
  • Esteve-Codina, Anna
  • Castel, Victoria
  • Cañete, Adela
  • Gut, Marta
  • Heath, Simon
  • Font de Mora, Jaime
Analysis of the methylome of tumor cell-free deoxyribonucleic acid (DNA; cfDNA) has emerged as a powerful non-invasive technique for cancer subtyping and prognosis. However, its application is frequently hampered by the quality and total cfDNA yield. Here, we demonstrate the feasibility of very low-input cfDNA for whole-methylome and copy-number profiling studies using enzymatic conversion of unmethylated cysteines [enzymatic methyl-seq (EM-seq)] to better preserve DNA integrity. We created a model for predicting genomic subtyping and prognosis with high accuracy. We validated our tool by comparing whole-genome CpG sequencing with in situ cohorts generated with bisulfite conversion and array hybridization, demonstrating that, despite the different techniques and sample origins, information on cfDNA methylation is comparable with in situ cohorts. Our findings support use of liquid biopsy followed by EM-seq to assess methylome of cancer patients, enabling validation in external cohorts. This advance is particularly relevant for rare cancers like neuroblastomas where liquid-biopsy volume is restricted by ethical regulations in pediatric patients., TRANSCAN-2 consortium LIQUIDHOPE by Fundación Científica de la Asociación Española Contra el Cáncer (TRNSC18001FON); Spanish Ministry of Science and Innovation (MICINN, PID2020-119323RB-I00 grant); ‘Sumemos muchas manos por los niños enfermos’ non-profit organization; Instituto de Salud Carlos III (ISCIII), Spain and ‘European Social Fund Plus (ESF+)’ of the European Union (Miguel Servet Program, CP20/00179, ISCIII-MICINN to E.V.); Fundación Científica de la Asociación Española Contra el Cáncer (PRDVA19004CORO to E.C.).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Liquidhope: methylome and genomic profiling from very limited quantities of plasma-derived DNA

  • Trinidad, Eva María
  • Vidal, Enrique
  • Coronado, Ester
  • Esteve-Codina, Anna
  • Castel, Victoria
  • Cañete, Adela
  • Gut, Marta
  • Heath, Simon
  • Font de Mora, Jaime
[EN] Analysis of the methylome of tumor cell-free deoxyribonucleic acid (DNA; cfDNA) has emerged as a powerful non-invasive technique for cancer subtyping and prognosis. However, its application is frequently hampered by the quality and total cfDNA yield. Here, we demonstrate the feasibility of very low-input cfDNA for whole-methylome and copy-number profiling studies using enzymatic conversion of unmethylated cysteines [enzymatic methyl-seq (EM-seq)] to better preserve DNA integrity. We created a model for predicting genomic subtyping and prognosis with high accuracy. We validated our tool by comparing whole-genome CpG sequencing with in situ cohorts generated with bisulfite conversion and array hybridization, demonstrating that, despite the different techniques and sample origins, information on cfDNA methylation is comparable with in situ cohorts. Our findings support use of liquid biopsy followed by EM-seq to assess methylome of cancer patients, enabling validation in external cohorts. This advance is particularly relevant for rare cancers like neuroblastomas where liquid-biopsy volume is restricted by ethical regulations in pediatric patients., TRANSCAN-2 consortium LIQUIDHOPE by Fundación Científica de la Asociación Española Contra el Cáncer (TRNSC18001FON); Spanish Ministry of Science and Innovation (MICINN, PID2020- 119323RB-I00 grant); Sumemos muchas manos por los niños enfermos non-profit organization; Instituto de Salud Carlos III (ISCIII), Spain and European Social Fund Plus (ESF+) of the European Union (Miguel Servet Program, CP20/00179, ISCIII-MICINN to E.V.); Fundación Científica de la Asociación Española Contra el Cáncer (PRDVA19004CORO to E.C.).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Liquidhope: methylome and genomic profiling from very limited quantities of plasma-derived DNA

  • Trinidad, Eva María
  • Vidal, Enrique
  • Coronado, Esther
  • Esteve-Codina, Anna
  • Castel, Victoria
  • Cañete, Adela
  • Gut, Marta
  • Heath, Simon
  • Font de Mora, Jaime
Analysis of the methylome of tumor cell-free deoxyribonucleic acid (DNA; cfDNA) has emerged as a powerful non-invasive technique for cancer subtyping and prognosis. However, its application is frequently hampered by the quality and total cfDNA yield. Here, we demonstrate the feasibility of very low-input cfDNA for whole-methylome and copy-number profiling studies using enzymatic conversion of unmethylated cysteines [enzymatic methyl-seq (EM-seq)] to better preserve DNA integrity. We created a model for predicting genomic subtyping and prognosis with high accuracy. We validated our tool by comparing whole-genome CpG sequencing with in situ cohorts generated with bisulfite conversion and array hybridization, demonstrating that, despite the different techniques and sample origins, information on cfDNA methylation is comparable with in situ cohorts. Our findings support use of liquid biopsy followed by EM-seq to assess methylome of cancer patients, enabling validation in external cohorts. This advance is particularly relevant for rare cancers like neuroblastomas where liquid-biopsy volume is restricted by ethical regulations in pediatric patients., TRANSCAN-2 consortium LIQUIDHOPE by Fundación Científica de la Asociación Española Contra el Cáncer (TRNSC18001FON); Spanish Ministry of Science and Innovation (MICINN, PID2020-119323RB-I00 grant); ‘Sumemos muchas manos por los niños enfermos’ non-profit organization; Instituto de Salud Carlos III (ISCIII), Spain and ‘European Social Fund Plus (ESF+)’ of the European Union (Miguel Servet Program, CP20/00179, ISCIII-MICINN to E.V.); Fundación Científica de la Asociación Española Contra el Cáncer (PRDVA19004CORO to E.C.).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Evaluation of circulating tumor DNA by electropherogram analysis and methylome profiling in high-risk neuroblastomas

  • Trinidad, Eva María
  • Juan-Ribelles, Antonio
  • Pisano, Giulia
  • Castel, Victoria
  • Cañete, Adela
  • Gut, Marta
  • Heath, Simon
  • Font de Mora, Jaime
Background: Liquid biopsy has emerged as a promising, non-invasive diagnostic approach in oncology because the analysis of circulating tumor DNA (ctDNA) reflects the precise status of the disease at diagnosis, progression, and response to treatment. DNA methylation profiling is also a potential solution for sensitive and specific detection of many cancers. The combination of both approaches, DNA methylation analysis from ctDNA, provides an extremely useful and minimally invasive tool with high relevance in patients with childhood cancer. Neuroblastoma is an extracranial solid tumor most common in children and responsible for up to 15% of cancer-related deaths. This high death rate has prompted the scientific community to search for new therapeutic targets. DNA methylation also offers a new source for identifying these molecules. However, the limited blood sample size which can be obtained from children with cancer and the fact that ctDNA content may occasionally be diluted by non-tumor cell-free DNA (cfDNA) complicate optimal quantities of material for high-throughput sequencing studies. Methods: In this article, we present an improved method for ctDNA methylome studies of blood-derived plasma from high-risk neuroblastoma patients. We assessed the electropherogram profiles of ctDNA-containing samples suitable for methylome studies, using 10 ng of plasma-derived ctDNA from 126 samples of 86 high-risk neuroblastoma patients, and evaluated several bioinformatic approaches to analyze DNA methylation sequencing data. Results: We demonstrated that enzymatic methyl-sequencing (EM-seq) outperformed bisulfite conversion-based method, based on the lower proportion of PCR duplicates and the higher percentage of unique mapping reads, mean coverage, and genome coverage. The analysis of the electropherogram profiles revealed the presence of nucleosomal multimers, and occasionally high molecular weight DNA. We established that 10% content of the mono-nucleosomal peak is sufficient ctDNA for successful detection of copy number variations and methylation profiles. Quantification of mono-nucleosomal peak also showed that samples at diagnosis contained a higher amount of ctDNA than relapse samples. Conclusions: Our results refine the use of electropherogram profiles to optimize sample selection for subsequent high-throughput analysis and support the use of liquid biopsy followed by enzymatic conversion of unmethylated cysteines to assess the methylomes of neuroblastoma patients., Supported by TRANSCAN-2 consortium LIQUIDHOPE by Fundación Científica de la Asociación Española Contra el Cáncer (TRNSC18001FON), by Spanish Ministry of Science and Innovation (PID2020-119323RB-I00 grant) and by “Sumemos muchas manos por los niños enfermos” non-profit organization.